China Pharma Holdings, Inc. (CPHI)

Market Cap	3.35M
Revenue (ttm)	5.54M
Net Income (ttm)	-4.74M
Shares Out	19.25M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	921,358
Open	0.170
Previous Close	0.159
Day's Range	0.152 - 0.176
52-Week Range	0.130 - 0.700
Beta	0.66
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About CPHI

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain;...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Zhilin Li
• Employees: 231
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CPHI
• Website: https://www.chinapharmaholdings.com

Financial Performance

In 2023, China Pharma Holdings's revenue was $7.01 million, a decrease of -13.48% compared to the previous year's $8.10 million. Losses were -$3.08 million, -22.50% less than in 2022.